
Cell panel screening

- Comprehensive, high-throughput, and cost-effective cell line screening services
- 600+ human cancer cell lines readily utilized for the single agent or combinatory drug screening
- 2D/3D culture system, spheroids or organoids, with the incubation options of conventional (3-7 days) and long-term (10-21 days)
- Integrated with downstream pharmacological services, with 360+ CDX models ready-for-use

Tumor cell panel and screening

- **670+** human cancer cell lines, covering **30+** cancer types
- **100+** mouse cancer cell lines covering **20+** cancer types
- **95** PDX-derived cell lines
- **1,400+** PDX for primary tumor cell line isolation
- **150+** engineered cell lines
- **9** drug resistant cell lines
- **Customized** cell line generation services (Lentivirus OE, etc.)




- **Viability/proliferation assay:** 2D & 3D CellTiter-Glo Cell Viability Assay, S3 Live Cell Analysis, BrdU ELISA, CyQUANT assay
- **Cell cycle & Apoptosis assay:** PI/BrdU FACS, Annexin V/Caspase 3 analysis with Incucyte S3
- **Phosphorylation cellular assay:** AlphaLISA Screening, HTRF Assay
- **Reporter assay:** NanoLuc system for Targeted Protein Degradation (TPD) screening, Other luciferase reporter assays

Flowchart of high-throughput screening platform










Cell seeding by Cybio Felix → Compound dispensing by ECHO655 → Plate reading → Data analysis and IC50 determination

<20 cell lines: 2-3 weeks | 20-50 cell lines: 3-4 weeks | 50-100 cell lines: 4-6 weeks | 100-200 cell lines: 6-8 weeks


Contact us

Technical: Pharmacology-BD-Translation@wuxiapptec.com
BD USA: mahnaz_arjomand@wuxiapptec.com
BD EU/UK/Israel: dave_madge@wuxiapptec.com
BD China: xu_longji@wuxiapptec.com
BD Japan: fumio_itoh@wuxiapptec.com
BD Korea: sycho@wuxiapptec.com

Case study: cell panel screening



Responsiveness of selective KRAS inhibitor correlates with KRAS mutation (3D culture, mutant-specific panel)



Validation of EGFRi-resistant mutation by AlphaLISA screening (EGFR engineered cell lines)

